{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T21:07:41Z","timestamp":1784408861693,"version":"3.55.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,9]]},"DOI":"10.7759\/cureus.85627","type":"journal-article","created":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T17:15:53Z","timestamp":1749489353000},"source":"Crossref","is-referenced-by-count":1,"title":["Fondaparinux Failure in Heparin-Induced Thrombocytopenia With Acute Limb Ischemia: A Case Report and Literature Review"],"prefix":"10.7759","author":[{"given":"Adam","family":"Bowen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dania","family":"Baraka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaleel","family":"Quasem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfarooq","family":"Alshaikhli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maha","family":"Bayya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1053\/j.jvca.2017.05.024","article-title":"Incidence and outcomes of heparin-induced thrombocytopenia in patients undergoing vascular surgery","volume":"31","author":"Chaudhry R","year":"2017","unstructured":"Chaudhry R, Wegner R, Zaki JF, et al.. Incidence and outcomes of heparin-induced thrombocytopenia in patients undergoing vascular surgery. J Cardiothorac Vasc Anesth. 2017, 31:1751-1757. 10.1053\/j.jvca.2017.05.024","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"ref2","article-title":"Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis. A retrospective analysis of 408 patients","volume":"94","author":"Greinacher A","year":"2005","unstructured":"Greinacher A, Farner B, Kroll H, et al.. Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis. A retrospective analysis of 408 patients. Thromb Haemost. 2005, 94:132-135.","journal-title":"Thromb Haemost"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1160\/TH04-12-0825","article-title":"Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis. A retrospective analysis of 408 patients","volume":"94","author":"Greinacher A","year":"2005","unstructured":"Greinacher A, Farner B, Kroll H, Kohlmann T, Warkentin TE, Eichler P. Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis. A retrospective analysis of 408 patients. Thromb Haemost. 2005, 94:132-5. 10.1160\/TH04-12-0825","journal-title":"Thromb Haemost"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-05-1938","article-title":"Anti-platelet factor 4\/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin","volume":"106","author":"Warkentin TE","year":"2005","unstructured":"Warkentin TE, Cook RJ, Marder VJ, et al.. Anti-platelet factor 4\/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. Blood. 2005, 106:3791-6. 10.1182\/blood-2005-05-1938","journal-title":"Blood"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1097\/MOH.0000000000000066","article-title":"Advances in the pathophysiology and treatment of heparin-induced thrombocytopenia","volume":"21","author":"McKenzie SE","year":"2014","unstructured":"McKenzie SE, Sachais BS. Advances in the pathophysiology and treatment of heparin-induced thrombocytopenia. Curr Opin Hematol. 2014, 21:380-7. 10.1097\/MOH.0000000000000066","journal-title":"Curr Opin Hematol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-11-709873","article-title":"Heparin-induced thrombocytopenia","volume":"129","author":"Arepally GM","year":"2017","unstructured":"Arepally GM. Heparin-induced thrombocytopenia. Blood. 2017, 129:2864-72. 10.1182\/blood-2016-11-709873","journal-title":"Blood"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc070346","article-title":"Heparin-induced thrombocytopenia associated with fondaparinux","volume":"356","author":"Warkentin TE","year":"2007","unstructured":"Warkentin TE, Maurer BT, Aster RH. Heparin-induced thrombocytopenia associated with fondaparinux. N Engl J Med. 2007, 356:2653-5; discussion 2653-5. 10.1056\/NEJMc070346","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1160\/TH07-09-0573","article-title":"Fondaparinux-related thrombocytopenia in a previous low-molecular-weight heparin (LMWH)-induced heparin-induced thrombocytopenia (HIT)","volume":"99","author":"Rota E","year":"2008","unstructured":"Rota E, Bazzan M, Fantino G. Fondaparinux-related thrombocytopenia in a previous low-molecular-weight heparin (LMWH)-induced heparin-induced thrombocytopenia (HIT). Thromb Haemost. 2008, 99:779-81. 10.1160\/TH07-09-0573","journal-title":"Thromb Haemost"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1160\/TH10-05-0284","article-title":"Fondaparinux thromboprophylaxis-associated heparin-induced thrombocytopenia syndrome complicated by arterial thrombotic stroke","volume":"104","author":"Salem M","year":"2010","unstructured":"Salem M, Elrefai S, Shrit MA, Warkentin TE. Fondaparinux thromboprophylaxis-associated heparin-induced thrombocytopenia syndrome complicated by arterial thrombotic stroke. Thromb Haemost. 2010, 104:1071-2. 10.1160\/TH10-05-0284","journal-title":"Thromb Haemost"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1160\/TH12-03-0201","article-title":"The serological profile of fondaparinux-associated heparin-induced thrombocytopenia syndrome","volume":"108","author":"Warkentin TE","year":"2012","unstructured":"Warkentin TE, Chakraborty AK, Sheppard JA, Griffin DK. The serological profile of fondaparinux-associated heparin-induced thrombocytopenia syndrome. Thromb Haemost. 2012, 108:394-6. 10.1160\/TH12-03-0201","journal-title":"Thromb Haemost"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13813","article-title":"Autoimmune heparin-induced thrombocytopenia","volume":"15","author":"Greinacher A","year":"2017","unstructured":"Greinacher A, Selleng K, Warkentin TE. Autoimmune heparin-induced thrombocytopenia. J Thromb Haemost. 2017, 15:2099-114. 10.1111\/jth.13813","journal-title":"J Thromb Haemost"},{"key":"ref12","doi-asserted-by":"crossref","DOI":"10.1002\/jca.20109","article-title":"Heparin-induced thrombocytopenia: an autoimmune disorder regulated through dynamic autoantigen assembly\/disassembly","volume":"22","author":"Cines DB","year":"2007","unstructured":"Cines DB, Rauova L, Arepally G, et al.. Heparin-induced thrombocytopenia: an autoimmune disorder regulated through dynamic autoantigen assembly\/disassembly. J Clin Apher. 2007, 22:1046-1052.","journal-title":"J Clin Apher"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018024489","article-title":"American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia","volume":"2","author":"Cuker A","year":"2018","unstructured":"Cuker A, Arepally GM, Chong BH, et al.. American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. Blood Adv. 2018, 2:3360-92. 10.1182\/bloodadvances.2018024489","journal-title":"Blood Adv"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1080\/09537104.2019.1652263","article-title":"Fondaparinux cross-reactivity in heparin-induced thrombocytopenia successfully treated with high-dose intravenous immunoglobulin and rivaroxaban","volume":"31","author":"Manji F","year":"2020","unstructured":"Manji F, Warkentin TE, Sheppard JI, Lee A. Fondaparinux cross-reactivity in heparin-induced thrombocytopenia successfully treated with high-dose intravenous immunoglobulin and rivaroxaban. Platelets. 2020, 31:124-7. 10.1080\/09537104.2019.1652263","journal-title":"Platelets"},{"key":"ref15","article-title":"Delayed-onset heparin-induced thrombocytopenia type-2 during fondiparinux (Arixtra) therapy","volume":"52","author":"Modi C","year":"2009","unstructured":"Modi C, Satani D, Cervellione KL, Cervantes J, Gintautas J. Delayed-onset heparin-induced thrombocytopenia type-2 during fondiparinux (Arixtra) therapy. Proc West Pharmacol Soc. 2009, 52:5-7.","journal-title":"Proc West Pharmacol Soc"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.12669\/pjms.37.2.3522","article-title":"Fondaparinux-associated thrombocytopenia","volume":"37","author":"Malik J","year":"2021","unstructured":"Malik J, Javed N, Kamin M. Fondaparinux-associated thrombocytopenia. Pak J Med Sci. 2021, 37:598-9. 10.12669\/pjms.37.2.3522","journal-title":"Pak J Med Sci"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1080\/08998280.2012.11928771","article-title":"Fondaparinux-associated heparin-induced thrombocytopenia","volume":"25","author":"Burch M","year":"2012","unstructured":"Burch M, Cooper B. Fondaparinux-associated heparin-induced thrombocytopenia. Proc (Bayl Univ Med Cent). 2012, 25:13-5. 10.1080\/08998280.2012.11928771","journal-title":"Proc (Bayl Univ Med Cent)"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.22067","article-title":"Heparin induced thrombocytopenia and re-thrombosis associated with warfarin and fondaparinux in a child","volume":"53","author":"Maurer SH","year":"2009","unstructured":"Maurer SH, Wilimas JA, Wang WC, Reiss UM. Heparin induced thrombocytopenia and re-thrombosis associated with warfarin and fondaparinux in a child. Pediatr Blood Cancer. 2009, 53:468-71. 10.1002\/pbc.22067","journal-title":"Pediatr Blood Cancer"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1055\/s-0040-1713175","article-title":"Failure of fondaparinux in autoimmune heparin-induced thrombocytopenia","volume":"4","author":"Sartori M","year":"2020","unstructured":"Sartori M, Cosmi B. Failure of fondaparinux in autoimmune heparin-induced thrombocytopenia. TH Open. 2020, 4:e305-8. 10.1055\/s-0040-1713175","journal-title":"TH Open"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1378\/chest.10-1599","article-title":"Prevalence and risk of preexisting heparin-induced thrombocytopenia antibodies in patients with acute VTE","volume":"140","author":"Warkentin TE","year":"2011","unstructured":"Warkentin TE, Davidson BL, B\u00fcller HR, et al.. Prevalence and risk of preexisting heparin-induced thrombocytopenia antibodies in patients with acute VTE. Chest. 2011, 140:366-73. 10.1378\/chest.10-1599","journal-title":"Chest"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/353311-fondaparinux-failure-in-heparin-induced-thrombocytopenia-with-acute-limb-ischemia-a-case-report-and-literature-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T17:15:53Z","timestamp":1749489353000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/353311-fondaparinux-failure-in-heparin-induced-thrombocytopenia-with-acute-limb-ischemia-a-case-report-and-literature-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,9]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.85627","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6,9]]}}}